1. Home
  2. TY vs GENB Comparison

TY vs GENB Comparison

Compare TY & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

HOLD

Current Price

$34.83

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$16.57

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TY
GENB
Founded
1929
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TY
GENB
Price
$34.83
$16.57
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$23.20
AVG Volume (30 Days)
34.4K
886.0K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
N/A
EPS
4.78
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16.58
P/E Ratio
$7.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.53
$11.00
52 Week High
$36.03
$17.42

Technical Indicators

Market Signals
Indicator
TY
GENB
Relative Strength Index (RSI) 48.98 62.89
Support Level $34.20 $11.73
Resistance Level $34.79 $16.75
Average True Range (ATR) 0.64 1.02
MACD -0.07 0.36
Stochastic Oscillator 28.68 78.29

Price Performance

Historical Comparison
TY
GENB

About TY Tri Continental Corporation

Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: